MediciNova, Inc. (MNOV) analyst actions
Rating and price-target actions on MNOV in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the MNOV overview →
1 measured MNOV analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria | Press release | +0.00% | -1.54% |
Keep exploring
More MNOV: earnings → · SEC filings → · MNOV overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ChromaDex Corporation (CDXC) | 118 | +0.80% | 61% |
| ADHERA THERAPEUTICS INC (ATRX) | 117 | 0.00% | 23% |
| SPROUTLY CDA INC (SRUTF) | 117 | 0.00% | 45% |
| Cannabis Sativa, Inc. (CBDS) | 114 | 0.00% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.